Literature DB >> 20576063

Loss of response to melatonin treatment is associated with slow melatonin metabolism.

W Braam1, I van Geijlswijk, Henry Keijzer, Marcel G Smits, Robert Didden, Leopold M G Curfs.   

Abstract

BACKGROUND: In some of our patients with intellectual disability (ID) and sleep problems, the initial good response to melatonin disappeared within a few weeks after starting treatment, while the good response returned only after considerable dose reduction. The cause for this loss of response to melatonin is yet unknown. We hypothesise that this loss of response is associated with slow melatonin metabolism.
METHOD: In this study, we determined melatonin clearance in two female (aged 61 and 6 years) and one male (aged 3 years) patients who had chronic insomnia, late melatonin onset and mild ID, and whose sleep quality worsened a few weeks after initial good response to melatonin treatment, suggesting melatonin tolerance. After a 3-week washout period, patients received melatonin 1.0, 0.5 or 0.1 mg, respectively. Salivary melatonin level was measured just before melatonin administration, and 2 and 4 h thereafter. After this melatonin clearance test, melatonin treatment was resumed with a considerably lower dose.
RESULTS: In all patients melatonin concentrations remained >50 pg/mL at 2 and 4 h after melatonin administration. After resuming melatonin treatment sleep problems disappeared. The same procedure was followed in three patients who did not show loss of response to melatonin after 6 months of treatment. In all patients in the control group melatonin concentrations decreased between 2 and 4 h after melatonin administration with a mean of 83%.
CONCLUSION: We hypothesise that loss of response to melatonin treatment can be caused by slow metabolisation of exogenous melatonin. As melatonin is metabolised in the liver almost exclusively by cytochrome P450 enzyme CYP1A2, this slow melatonin metabolism is probably due to decreased activity/inducibility of CYP1A2. In patients with loss of response to melatonin, a melatonin clearance test should be considered and a considerably dose reduction is advised.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20576063     DOI: 10.1111/j.1365-2788.2010.01283.x

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  17 in total

1.  Melatonin in Children with Autism Spectrum Disorders: How Does the Evidence Fit Together?

Authors:  Olivia J Veatch; Suzanne E Goldman; Karen W Adkins; Beth A Malow
Journal:  J Nat Sci       Date:  2015

Review 2.  Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of current literature.

Authors:  Esmée M S Vural; Barbara C van Munster; Sophia E de Rooij
Journal:  Drugs Aging       Date:  2014-06       Impact factor: 3.923

3.  Genetic variation in melatonin pathway enzymes in children with autism spectrum disorder and comorbid sleep onset delay.

Authors:  Olivia J Veatch; Julie S Pendergast; Melissa J Allen; Roberta M Leu; Carl Hirschie Johnson; Sarah H Elsea; Beth A Malow
Journal:  J Autism Dev Disord       Date:  2015-01

4.  Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD), and Irregular Sleep-Wake Rhythm Disorder (ISWRD). An Update for 2015: An American Academy of Sleep Medicine Clinical Practice Guideline.

Authors:  R Robert Auger; Helen J Burgess; Jonathan S Emens; Ludmila V Deriy; Sherene M Thomas; Katherine M Sharkey
Journal:  J Clin Sleep Med       Date:  2015-10-15       Impact factor: 4.062

Review 5.  Sleep and Epilepsy: a Focused Review of Pathophysiology, Clinical Syndromes, Co-morbidities, and Therapy.

Authors:  J Layne Moore; Diego Z Carvalho; Erik K St Louis; Carl Bazil
Journal:  Neurotherapeutics       Date:  2021-03-30       Impact factor: 7.620

Review 6.  Circadian Rhythm Sleep-Wake Disorders: a Contemporary Review of Neurobiology, Treatment, and Dysregulation in Neurodegenerative Disease.

Authors:  Tyler A Steele; Erik K St Louis; Aleksandar Videnovic; R Robert Auger
Journal:  Neurotherapeutics       Date:  2021-04-12       Impact factor: 7.620

7.  Evaluation of sleep, puberty and mental health in children with long-term melatonin treatment for chronic idiopathic childhood sleep onset insomnia.

Authors:  Ingeborg M van Geijlswijk; Robert H Mol; Toine C G Egberts; Marcel G Smits
Journal:  Psychopharmacology (Berl)       Date:  2011-02-22       Impact factor: 4.530

8.  "Diagnosis by behavioral observation" home-videosomnography - a rigorous ethnographic approach to sleep of children with neurodevelopmental conditions.

Authors:  Osman S Ipsiroglu; Yi-Hsuan Amy Hung; Forson Chan; Michelle L Ross; Dorothee Veer; Sonja Soo; Gloria Ho; Mai Berger; Graham McAllister; Heinrich Garn; Gerhard Kloesch; Adriano Vilela Barbosa; Sylvia Stockler; William McKellin; Eric Vatikiotis-Bateson
Journal:  Front Psychiatry       Date:  2015-03-17       Impact factor: 4.157

Review 9.  Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives.

Authors:  Sylvie Tordjman; Imen Najjar; Eric Bellissant; George M Anderson; Marianne Barburoth; David Cohen; Nemat Jaafari; Olivier Schischmanoff; Rémi Fagard; Enas Lagdas; Solenn Kermarrec; Sophie Ribardiere; Michel Botbol; Claire Fougerou; Guillaume Bronsard; Julie Vernay-Leconte
Journal:  Int J Mol Sci       Date:  2013-10-14       Impact factor: 5.923

10.  Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial.

Authors:  P Gringras; C Gamble; A P Jones; L Wiggs; P R Williamson; A Sutcliffe; P Montgomery; W P Whitehouse; I Choonara; T Allport; A Edmond; R Appleton
Journal:  BMJ       Date:  2012-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.